Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
MECHELEN, Belgium, July 29, 2016 -- Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Federated Equity Management Company of Pennsylvania .
Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 26 July 2016 from Federated Investors, Inc. and Federated Equity Management Company of Pennsylvania, who notified that funds[2] managed by Federated Equity Management hold 2,289,479 shares of the 46,109,508 currently outstanding Galapagos shares. On 20 July 2016, a share sale resulted in a decrease below the 5% notification threshold of Galapagos' voting rights. The full transparency notice is available on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 2, Phase 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 460 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
| Investors: | Media: |
| Elizabeth Goodwin | Evelyn Fox |
| VP IR & Corporate Communications | Director Communications |
|
+1 781 460 1784 Paul van der Horst Director IR & Business Development +31 6 53 725 199 |
+31 6 53 591 999 [email protected] |
| [email protected] |
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.
[2] Federated Kaufmann Fund, Federated Kaufmann Fund II and Federated Kaufmann Small Cap Fund.
HUG#2031773
